AOP Orphan reports full validity of arbitral award against PharmaEssentia
Since 2017, PharmaEssentia had repeatedly attempted to terminate the agreement with AOP Orphan concerning BESREMi® (Ropeginterferon alfa-2b). After two and a half years of arbitral proceedings, in October 2020, the ICC Arbitral Tribunal issued its award in the matter. The arbitral award states that PharmaEssentia’s multiple attempts to terminate the agreement were unjustified, and that AOP Orphan is entitled to payment of damages of approximately EUR 142 million for project delays caused by PharmaEssentia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005949/en/
Dr Rudolf Widmann, Chief Therapeutics Development Officer, Board Member, Founder, AOP Orphan Pharmaceuticals AG. (Copyright: bell&sass)
In December 2020, PharmaEssentia filed an application to set aside this arbitral award with the Frankfurt Higher Regional Court, arguing that the award violated public order and PharmaEssentia’s right to be heard. The Frankfurt Higher Regional Court, a German court with major experience in handling this kind of proceedings, called a hearing within less than two months of PharmaEssentia’s filing its setting aside application.
Award declared enforceable
Today, the Frankfurt Higher Regional Court announced its decision. As anticipated, the Court dismissed PharmaEssentia's set aside application, confirming that both parties had sufficient opportunity to be heard, that all evidence brought before the Arbitral Tribunal was duly taken into consideration, and that the public order was fully respected.
Thus, the award as issued by the ICC Arbitral Tribunal in October 2020 has now been declared enforceable by Frankfurt Higher Regional Court, and AOP Orphan can pursue its enforcement in Germany and elsewhere. An appeal to the German Supreme Court is possible but would not hinder the enforcement of the award.
Rudolf Widmann, Chief Therapeutics Development Officer and Member of the Board of AOP Orphan, explains: “AOP Orphan has always complied with its contractual obligations and is entitled to compensation by PharmaEssentia, following their repeated attempts to boycott the joint project and success of BESREMi®. We encourage PEC to accept the arbitral award and work towards cooperative efforts to exploit the full value of BESREMi® in the interest of patients and stakeholders of both companies. AOP Orphan has tried to find solutions several times - I would have preferred to invest time and money into making this highly promising drug available to patients with blood cancer, instead of investing it into expensive lawsuits.”
About BESREMi®
BESREMi® is a long-acting, mono-pegylated proline interferon (ATC L03AB15). Its unique pharmacokinetic properties offer a new level of tolerability. BESREMi® is designed to be conveniently self-administered subcutaneously with a pen once every two weeks, or monthly after stabilization of hematological parameters. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. Ropeginterferon alfa-2b was discovered by PharmaEssentia, a long-term partner of AOP Orphan. In 2009, AOP Orphan in-licensed the exclusive rights for clinical development and commercialization of Ropeginterferon alfa-2b in PV and other MPNs for European, Commonwealth of Independent States (CIS), and Middle Eastern markets.
For the EMA Summary of Product Characteristics please visit: https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf
AOP Orphan Pharmaceuticals AG is an international pharmaceutical company with its headquarters in Vienna and a focus on rare and special diseases. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families but also the doctors and care professionals treating them. In the third quarter of 2020, AOP Orphan took over Amomed Pharma GmbH and SciPharm S.a.r.l., two European health care companies, thus continuing its consistent path of growth into a pan-European health care group specializing in special diseases with complex management.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005949/en/
Contact information
AOP Orphan Pharmaceuticals AG
Ms. Nina Roth, MAS
T: +43 676 3131509
E: nina.roth@aoporphan.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG’s MidOcean Energy Completes Acquisition of Interest in Canada from PETRONAS17.12.2025 10:58:00 EET | Press release
MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the completion of its acquisition of a 20% interest in PETRONAS’ key entities in Canada. The transaction includes a 20% interest in the North Montney Upstream Joint Venture (“NMJV”), which holds PETRONAS’ upstream investment in Canada, and a 20% interest in the North Montney LNG Limited Partnership (“NMLLP”), which holds PETRONAS’ 25% participating interest in the LNG Canada Project. This strategic investment positions MidOcean across the LNG value chain, securing upstream resources and downstream liquefaction through the LNG Canada Project, with around 0.7 MTPA of associated LNG and potential to grow further. RBC Capital Markets acted as financial advisor to MidOcean, and Latham & Watkins acted as legal advisor. About EIG EIG is a leading institutional investor in the global energy and infrastru
Nexo Announces Landmark Crypto Partnership with Tennis Australia for Australian Open and Summer of Tennis17.12.2025 10:00:00 EET | Press release
Nexo, the premier digital assets platform, has entered a landmark multi-year global partnership with Tennis Australia, becoming the Official Crypto Partner of the Australian Open and the Summer of Tennis, including the United Cup, Adelaide International, Brisbane International, and Hobart International. This agreement marks the first time a digital asset company has partnered with a Grand Slam tournament, affirming Nexo’s prestige, long-term vision, and leadership at the intersection of elite sport and digital assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216497915/en/ Antoni Trenchev, Co-founder, Nexo, noted: “The Australian Open stands at the intersection of excellence and ambition – precisely where Nexo positions itself. Our partnership reflects a shared commitment to disciplined performance and long-term thinking. We are honored to join Tennis Australia in elevating the sport while showcasing the value of int
Outpost24 Secures New Investment to Scale its Exposure Management and Identity Security Solutions17.12.2025 09:00:00 EET | Press release
Outpost24, a leader in exposure management and identity security, today announced a new investment from Vitruvian Partners to fuel its next phase of global growth. This significant new funding will accelerate innovation across the company's platform, with a focus on integrating AI capabilities to optimize how security teams identify and neutralize critical vulnerabilities. The only European vendor recognized as an overall leader in the 2025 KuppingerCole Leadership Compass Report for Attack Surface Management, Outpost24 delivers a distinct approach to cyber defence that empowers security teams to gain a complete understanding of their digital and human risk landscape. Last week, Outpost24 announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks the company's entry into the Zero Trust Workforce Access market and lays the foundation for its identity security division, Specops, to offer a unified appr
VeritasChain Unveils VAP Architecture, New Auditability Research, and Confirms Submissions to 58 Regulators Globally17.12.2025 09:00:00 EET | Press release
VeritasChain today unveiled its Verifiable AI Provenance Framework (VAP) architecture, published new research on verifiable audit trails, and confirmed informational submissions to 58 regulatory authorities across 43 jurisdictions. These milestones advance VeritasChain’s mission to establish a global framework for verifiable auditability in AI and algorithmic trading. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216433807/en/ Map indicates jurisdictions where regulatory outreach or informational submissions have been made as of Dec 2025. Verifiable AI Provenance Framework (VAP) VAP is a layered assurance architecture designed for independent verification of AI decision-making. It is not a single product, but a framework defining how cryptographic evidence and third-party verification interoperate across diverse systems. The architecture records decision-to-execution events as immutable audit trails, facilitating regulat
New Published Data Confirms Nemluvio ® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermatology and Venereology. Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response. Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as per
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom